Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 송태진 | * |
dc.date.accessioned | 2023-07-27T16:31:09Z | - |
dc.date.available | 2023-07-27T16:31:09Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 2287-6391 | * |
dc.identifier.issn | 2287-6405 | * |
dc.identifier.other | OAK-33772 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265140 | - |
dc.description.abstract | Background and Purpose Moderate-intensity statin plus ezetimibe versus high-intensity statin alone may provide a greater low-density lipoprotein cholesterol (LDL-C) reduction in patients with recent ischemic stroke. Methods This randomized, open-label, controlled trial assigned patients with recent ischemic stroke <90 days to rosuvastatin/ezetimibe 10/10 mg once daily (ROS10/EZT10) or to rosuvastatin 20 mg once daily (ROS20). The primary endpoint was LDL-C reduction & GE;50% from baseline at 90 days. Key secondary endpoints were LDL-C <70 mg/dL and multiple lipid goal achievement, and composite of major vascular events. Results Of 584 randomized, 530 were included in the modified intention-to-treat analysis. The baseline LDL-C level was 130.2 & PLUSMN;34.7 mg/dL in the ROS10/EZT10 group and 131.0 & PLUSMN;33.9 mg/dL in the ROS20 group. The primary endpoint was achieved in 198 patients (72.5%) in the ROS10/EZT10 group and 148 (57.6%) in the ROS20 group (odds ratio [95% confidence interval], 1.944 [1.352-2.795]; P= 0.0003). LDL-C level <70 mg/dL was achieved in 80.2% and 65.4% in the ROS10/EZT10 and ROS20 groups (P=0.0001). Multiple lipid goal achievement rate was 71.1% and 53.7% in the ROS10/EZT10 and ROS20 groups (P<0.0001). Major vascular events occurred in 1 patient in the ROS10/EZT10 group and 9 in the ROS20 group (P=0.0091). The adverse event rates did not differ between the two groups. Conclusion Moderate-intensity rosuvastatin plus ezetimibe was superior to high-intensity rosuvastatin alone for intensive LDL-C reduction in patients with recent ischemic stroke. With the combination therapy, more than 70% of patients achieved LDL-C reduction & GE;50% and 80% had an LDL-C <70 mg/dL at 90 days. | * |
dc.language | English | * |
dc.publisher | KOREAN STROKE SOC | * |
dc.subject | Stroke | * |
dc.subject | LDL cholesterol | * |
dc.subject | Rosuvastatin | * |
dc.subject | Ezetimibe | * |
dc.subject | Target goal | * |
dc.title | Moderate-Intensity Rosuvastatin Plus Ezetimibe Versus High-Intensity Rosuvastatin for Target Low-Density Lipoprotein Cholesterol Goal Achievement in Patients With Recent Ischemic Stroke: A Randomized Controlled Trial | * |
dc.type | Article | * |
dc.relation.issue | 2 | * |
dc.relation.volume | 25 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 242 | * |
dc.relation.lastpage | + | * |
dc.relation.journaltitle | JOURNAL OF STROKE | * |
dc.identifier.doi | 10.5853/jos.2022.02957 | * |
dc.identifier.wosid | WOS:001021497000006 | * |
dc.identifier.scopusid | 2-s2.0-85163110654 | * |
dc.author.google | Hong, Keun-Sik | * |
dc.author.google | Bang, Oh Young | * |
dc.author.google | Park, Jong -Ho | * |
dc.author.google | Jung, Jin-Man | * |
dc.author.google | Lee, Sang -Hun | * |
dc.author.google | Song, Tae-Jin | * |
dc.author.google | Nam, Hyo Suk | * |
dc.author.google | Park, Hee-Kwon | * |
dc.author.google | Jung, Keun-Hwa | * |
dc.author.google | Heo, Sung Hyuk | * |
dc.author.google | Koo, Jaseong | * |
dc.author.google | Yu, Kyung-Ho | * |
dc.author.google | Park, Kwang-Yeol | * |
dc.author.google | Kim, Chi Kyung | * |
dc.author.google | Park, Hong-Kyun | * |
dc.author.google | Lee, Jiyoon | * |
dc.author.google | Lee, Juneyoung | * |
dc.author.google | Seo, Woo-Keun | * |
dc.contributor.scopusid | 송태진(55507164200) | * |
dc.date.modifydate | 20240304123954 | * |